Drugs / Allogeneic NK cell
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04599452 | Dec 2020 → Dec 2023 | acute myeloid leukemia | The Second Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04599426 | Dec 2020 → Dec 2023 | myelodysplastic syndrome with excess blasts | The Second Hospital of Shandong University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic NK cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04599426 ↗ |
| Modality | Cell therapy | “allogenic NK cells therapy” NCT04599426 ↗ |